Multicystic mesothelioma of the peritoneum – 6 cases
- 5 surgery, 1 CRS-HIPEC – 6/6 alive

Malignant mesothelioma – 27 cases
- first-line treatment: preoperative chemotherapy (14 cases), surgery only (3), chemotherapy only (5), adjuvant chemotherapy (3) or palliative treatment (2)
- response rate to cisplatin-pemetrexed = 50% (6/12 cases)
- hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) in 19 patients (3 upfront, 12 after neoadjuvant therapy, 6 after tumour progression

5-year EFS 45.1%, 5-year OS 82.3% (median follow-up 6.7 years)

Conclusions:
Paediatric mesothelioma is exceptional and seems to be different from its adult counterpart with few asbestos exposures, more peritoneal primary, and a better outcome.
The cisplatin-pemetrexed regimen showed promising efficacy. Relapses could be salvaged with active therapy including CRS-HIPEC.